<DOC>
	<DOCNO>NCT00055432</DOCNO>
	<brief_summary>This study hop evaluate whether combination Gemzar plus Alimta beneficial effect patient recurrent platinum-sensitive platinum-resistant ovarian peritoneal cancer . Treatments weekly two week , 3rd week repeat every 21 day . Side effect overall safety treatment also monitor evaluate . In addition , Quality Life questionnaire part study help measure patient perceive benefit drawback treatment regimen .</brief_summary>
	<brief_title>Gemzar ( Gemcitabine ) Alimta ( Pemetrexed ) Treatment Patients With Recurrent Platinum-Sensitive Platinum-Resistant Ovarian Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must disease measure . Patients must meet criterion either platinumresistant platinumsensitive ovarian peritoneal cancer . Patients may one prior platinumbased chemotherapy regimen . Patients must willing able stop aspirin NSAID medication immediately time treatment cycle ( approx . 58 day ) Patients must normal kidney function . Patients may Low Malignant Potential Borderline Ovarian Tumor . Patients may receive pelvic abdominal radiotherapy . Patients must evidence receive treatment another cancer within last 5 year . Patients must diagnose heart attack last 6 month . Patients unwilling unable take folic acid tablet , vitamin B12 injection dexamethasone tablet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>platinum-resistant</keyword>
	<keyword>platinum-sensitive</keyword>
	<keyword>folate receptor antagonist</keyword>
</DOC>